| Filed On | Filing |
|---|---|
| 09 Nov 2026 |
Form 4: Bogle Grant C., Director
Granted 66,700 Stock Option |
| 09 Nov 2026 |
Form 3: Bogle Grant C., Director
No securities owned |
| 09 Nov 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On November 9, 2026, the Board of Directors (the "Board") of Immuneering Corporation (the “Company”) appointed Grant C. Bogle, MBA, to serve as a member of the Company's Board as a Class III Director. Mr. Bogle will receive compensation ... |
| 29 Oct 2026 | 10-Q |
| 29 Oct 2026 |
8-K: Results of Operations and Financial Condition
- Phase 2 pancreatic cancer follow-up extended as patients on atebimetinib combinations live longer than projected - |
| 05 Aug 2026 | 10-Q |
| 05 Aug 2026 |
8-K: Results of Operations and Financial Condition
Immuneering Reports Second Quarter 2026 Financial Results and Provides Business Updates- 17.3 month median overall survival in 55 first-line pancreatic cancer patients treated with atebimetinib in combination with chemotherapy, reported ... |
| 28 Jul 2026 | SCHEDULE 13G |
| 17 Jul 2026 |
Form 4: Gengos Andrew, Chief Financial Officer
Granted 650,000 Stock Option |
| 16 Jul 2026 |
Form 3: Gengos Andrew, Chief Financial Officer
Holds 225,000 shares of Class A Common Stock |
| 24 Jun 2026 |
Form 4: Zeskind Benjamin J., Director
Bought 2,400 shares ($10.9K) |
| 16 Jun 2026 |
Form 4: Hall Brett Matthew, CHIEF SCIENTIFIC OFFICER
Bought 6,035 shares ($25K) |
| 15 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On June 11, 2026, the Board of Directors (the “Board”) of Immuneering Corporation (the “Company”) appointed Andrew Gengos as the Chief Financial Officer and Treasurer of the Company, to become effective on the commencement of his employm... |
| 11 Jun 2026 |
Form 4: Schall Thomas J., Director
Granted 33,350 Stock Option |
| 11 Jun 2026 |
Form 4: Hausman Diana, Director
Granted 33,350 Stock Option |
| 11 Jun 2026 |
Form 4: Carpenter Robert J, Director
Granted 33,350 Stock Option |
| 11 Jun 2026 |
Form 4: Keating Laurie, Director
Granted 33,350 Stock Option |
| 11 Jun 2026 |
Form 4: Feinberg Peter, Director
Granted 33,350 Stock Option |
| 11 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 11, 2026, Immuneering Corporation (the “Company”) held its Annual Meeting of Stockholders. A total of 44,495,059 shares of the Company’s Class A common stock were present in person or represented by proxy at the meeting, represen... |
| 01 Jun 2026 |
8-K: Other Events
On June 1, 2026, Immuneering Corporation (the "Company") announced updated data from its ongoing Phase 2a clinical trial evaluating atebimetinib (formerly known as IMM-1-104), a once-daily oral mitogen-activated protein kinase kinase (or... |
Loading...